imipramine has been researched along with Dysthymia in 20 studies
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a multicenter study, 410 patients with early-onset primary dysthymia were treated in a randomized prospective fashion with sertraline, imipramine, or placebo." | 9.09 | Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: effects on personality. ( Chapman, D; Harrison, W; Hellerstein, DJ; Kocsis, JH; Stewart, JW, 2000) |
| "In a multicenter, double-blind, parallel-group trial, 416 patients with a diagnosis of early-onset primary dysthymia (DSM-III-R) of at least 5 years' duration without concurrent major depression were randomly assigned to 12 weeks of acute-phase therapy with sertraline, imipramine, or placebo." | 9.08 | Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. ( Davidson, J; Halbreich, U; Hellerstein, DJ; Kocsis, JH; Rosenbaum, J; Shelton, R; Yonkers, K; Zisook, S, 1997) |
| " We compared the prevalence of anger attacks in 168 outpatients with atypical depression or primary dysthymia with 38 normal subjects and tested the effect of treatment on anger attacks in a double-blind, placebo-controlled trial of sertraline versus imipramine." | 9.08 | A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. ( Fava, M; Nierenberg, AA; Pearlstein, T; Quitkin, FM; Rosenbaum, JF; Stone, A; Zisook, S, 1997) |
| "An international, multicenter, placebo-controlled study was undertaken to determine the safety and antidepressant efficacy of moclobemide, a new reversible inhibitor of monoamine oxidase A, and imipramine in the treatment of dysthymia (DSM-III-R)." | 9.08 | Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group. ( Amrein, R; Stabl, M; Versiani, M, 1997) |
| "The subsequent delineation of dysthymia in DSM-III and its future editions as well as ICD." | 6.40 | Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide. ( Versiani, M, 1998) |
| "Subjects diagnosed with DSM-III-R chronic major depressive disorder or double depression (dysthymia with concurrent major depressive episode) were randomly assigned between February 1993 and December 1994 to 12 weeks of double-blind treatment with flexibly-dosed sertraline or imipramine, with crossover to the alternate drug in the absence of response." | 5.12 | Acute worsening of chronic depression during a double-blind, randomized clinical trial of antidepressant efficacy: differences by sex and menopausal status. ( Clary, CM; Harvey, AT; Kornstein, SG; Silkey, BS, 2007) |
| "This was a multisite study in which outpatients with chronic major depression (with or without concurrent dysthymia), who failed to respond to 12 weeks of double-blind treatment with either sertraline hydrochloride (n = 117) or imipramine hydrochloride (n = 51), were crossed over or switched to 12 additional weeks of double-blind treatment with the alternate medication." | 5.10 | Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. ( Fawcett, J; Gelenberg, AJ; Harrison, W; Hirschfeld, RM; Howland, RH; Keller, MB; Klein, DN; Kocsis, JH; Koran, LM; Kornstein, SG; LaVange, LM; Rush, AJ; Russell, JM; Schatzberg, AF; Thase, ME, 2002) |
| "In a multicenter study, 410 patients with early-onset primary dysthymia were treated in a randomized prospective fashion with sertraline, imipramine, or placebo." | 5.09 | Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: effects on personality. ( Chapman, D; Harrison, W; Hellerstein, DJ; Kocsis, JH; Stewart, JW, 2000) |
| ", major depression superimposed on dysthymia) were randomly assigned to 12 weeks of double-blind treatment with sertraline or with imipramine after placebo washout." | 5.09 | Gender differences in treatment response to sertraline versus imipramine in chronic depression. ( Davis, SM; Gelenberg, AJ; Harrison, WM; Keitner, GI; Keller, MB; Kornstein, SG; McCullough, JP; Schatzberg, AF; Thase, ME; Yonkers, KA, 2000) |
| "After 12 weeks of acute phase treatment in a double-blind, randomized, parallel-group, multi-center trial of sertraline or imipramine, patients with chronic depression (> or = 2 years in major depression, or major depression superimposed on dysthymia) continued study drug for 16 weeks." | 5.09 | Sertraline versus imipramine to prevent relapse in chronic depression. ( DeBattista, C; Friedman, RA; Gelenberg, AJ; Hirschfeld, RM; Howland, RH; Keller, MB; Klein, D; Kocsis, JH; Koran, LM; Kornstein, SG; LaVange, LM; Rush, AJ; Schatzberg, AF; Thase, ME, 2001) |
| "In a multicenter, double-blind, parallel-group trial, 416 patients with a diagnosis of early-onset primary dysthymia (DSM-III-R) of at least 5 years' duration without concurrent major depression were randomly assigned to 12 weeks of acute-phase therapy with sertraline, imipramine, or placebo." | 5.08 | Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes. ( Davidson, J; Halbreich, U; Hellerstein, DJ; Kocsis, JH; Rosenbaum, J; Shelton, R; Yonkers, K; Zisook, S, 1997) |
| " We compared the prevalence of anger attacks in 168 outpatients with atypical depression or primary dysthymia with 38 normal subjects and tested the effect of treatment on anger attacks in a double-blind, placebo-controlled trial of sertraline versus imipramine." | 5.08 | A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. ( Fava, M; Nierenberg, AA; Pearlstein, T; Quitkin, FM; Rosenbaum, JF; Stone, A; Zisook, S, 1997) |
| "An international, multicenter, placebo-controlled study was undertaken to determine the safety and antidepressant efficacy of moclobemide, a new reversible inhibitor of monoamine oxidase A, and imipramine in the treatment of dysthymia (DSM-III-R)." | 5.08 | Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group. ( Amrein, R; Stabl, M; Versiani, M, 1997) |
| "1 years; mean duration of dysthymia = 23+/-13 years) and high rates of comorbidity, 52% of patients achieved a satisfactory therapeutic response to sertraline or imipramine (by a conservative, intent-to-treat analysis)." | 5.08 | The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. ( Davis, SM; Fawcett, JA; Gelenberg, AJ; Harrison, WM; Hirschfeld, RM; Keller, MB; Klein, DN; Kocsis, JH; Koran, LM; Kornstein, SG; Markowitz, JC; McCullough, JP; Rush, AJ; Russell, JM; Thase, ME, 1998) |
| "Sertraline was significantly superior in tolerability with less discontinuations due to adverse events (10." | 2.71 | Sertraline is more effective than imipramine in the treatment of non-melancholic depression: results from a multicentre, randomized study. ( Baca, E; García-Toro, M; González de Chávez, M; Pérez-Arnau, F; Porras-Chavarino, A, 2003) |
| "Although the mean duration of dysthymia was about 30 years and almost half of the patients had previous episodes of major depression, only 41." | 2.68 | The undertreatment of dysthymia. ( Davidson, J; Halbreich, U; Koran, L; Pearlstein, T; Shelton, RC; Thase, ME; Yonkers, KA, 1997) |
| "The subsequent delineation of dysthymia in DSM-III and its future editions as well as ICD." | 2.40 | Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide. ( Versiani, M, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (55.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baca, E | 1 |
| González de Chávez, M | 1 |
| García-Toro, M | 1 |
| Pérez-Arnau, F | 1 |
| Porras-Chavarino, A | 1 |
| Harvey, AT | 1 |
| Silkey, BS | 1 |
| Kornstein, SG | 6 |
| Clary, CM | 1 |
| Kocsis, JH | 6 |
| Zisook, S | 2 |
| Davidson, J | 2 |
| Shelton, R | 1 |
| Yonkers, K | 1 |
| Hellerstein, DJ | 2 |
| Rosenbaum, J | 1 |
| Halbreich, U | 2 |
| Shelton, RC | 1 |
| Yonkers, KA | 2 |
| Koran, L | 1 |
| Thase, ME | 7 |
| Pearlstein, T | 2 |
| Fava, M | 1 |
| Nierenberg, AA | 1 |
| Quitkin, FM | 2 |
| Stone, A | 1 |
| Rosenbaum, JF | 1 |
| Buni, TM | 1 |
| de Jonghe, F | 1 |
| Versiani, M | 2 |
| Amrein, R | 1 |
| Stabl, M | 1 |
| Rush, AJ | 5 |
| Koran, LM | 4 |
| Keller, MB | 6 |
| Markowitz, JC | 3 |
| Harrison, WM | 4 |
| Miceli, RJ | 1 |
| Fawcett, JA | 2 |
| Gelenberg, AJ | 5 |
| Hirschfeld, RM | 4 |
| Klein, DN | 4 |
| McCullough, JP | 3 |
| Schatzberg, AF | 5 |
| Russell, JM | 2 |
| Davis, SM | 3 |
| Miller, IW | 1 |
| Keitner, GI | 2 |
| Schlager, DS | 1 |
| Stewart, JW | 2 |
| McGrath, PJ | 1 |
| Bruder, GE | 1 |
| Bekaroğlu, M | 1 |
| Değer, O | 1 |
| Karahan, SC | 1 |
| Bilici, M | 1 |
| Soylu, C | 1 |
| Orem, A | 1 |
| Chapman, D | 1 |
| Harrison, W | 2 |
| Marsland, TW | 1 |
| Newton, W | 1 |
| Howland, RH | 2 |
| Friedman, RA | 1 |
| DeBattista, C | 1 |
| Klein, D | 1 |
| LaVange, LM | 2 |
| Reich, J | 1 |
| Fawcett, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cognitive Remediation for Neuropsychological Impairment in Compulsive Hoarding[NCT01451697] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2011-07-31 | Completed | ||
| A Randomized, Double-Blind, Support-of-Concept Phase 2 Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)[NCT03866174] | Phase 2 | 104 participants (Actual) | Interventional | 2019-10-15 | Completed | ||
| Medication Treatment Following Neuropsychologic, Dichotic and f-MRI Tests in Depressed Outpatients With Repeat f-MRI Following Treatment[NCT00296777] | Phase 4 | 28 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Dichotic Listening as a Predictor of Placebo and Medication Response in Depression[NCT00296725] | Phase 1/Phase 2 | 25 participants (Actual) | Interventional | 1994-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The HAM-D is a commonly used measure of the severity of depression. While several versions exist consisting of different numbers of items, virtually all include the original 17. Each item is scored from on a 3 or 5 point scale (so, from 0-2 or 0-4), with 0 indicating the item is not present and the highest item score indicating it is present nearly all the time to the severest extent. Item scores are added to obtain a total HAM-D score. Minimum possible score is 0 (indicating none of the 17 items is present), maximal possible score is 52. By convention, scores of <=7 are accepted as indicating remission and scores that have decreased >= 50% from pre-treatment indicate positive response. Higher scores indicate worse depression, while lower scores indicate milder depression or lack of depressive symptoms." (NCT00296725)
Timeframe: 6 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Fluoxetine | 10 |
| Imipramine | 9 |
"The CGI consists of two ratings: 1) Global Severity (CGI-S) and 2) Global Improvement (CGI-I), both having seven possible ratings, each from 1-7. Ratings on the CGI-S are: 1=No psychopathology 2=Minimal psychopathology 3=Mild psychopathology 4=Moderate psychopathology 5=Moderately severe psychopathology 6=Severe psychopathology 7 Extreme psychopathology. CGI-I ratings are rated for how the past week's psychopathology compares to the week immediately prior to start of treatment and includes: 1=Very much improved 2=much improved 3=minimally improved 4=Unchanged 5=minimally worse 6=much worse 7=very much worse. Scores on both thus range from 1-7 with lower scores indicating less psychopathology/greater improvement, respectively, and higher scores indicating more psychopathology/less improvement, respectively. We define response as a CGI-I of 1 or 2; nonresponse is all other ratings (i.e., CGI-I = 3 or higher." (NCT00296725)
Timeframe: 6 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Fluoxetine | 7 |
| Imipramine | 4 |
1 review available for imipramine and Dysthymia
| Article | Year |
|---|---|
Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Clinical Trials as Topic; Comor | 1998 |
16 trials available for imipramine and Dysthymia
| Article | Year |
|---|---|
Sertraline is more effective than imipramine in the treatment of non-melancholic depression: results from a multicentre, randomized study.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Depressive Disorder, Major; Dysthymic Disorder; Femal | 2003 |
Acute worsening of chronic depression during a double-blind, randomized clinical trial of antidepressant efficacy: differences by sex and menopausal status.
Topics: Adult; Cross-Over Studies; Depressive Disorder, Major; Disease Progression; Double-Blind Method; Dys | 2007 |
Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: psychosocial outcomes.
Topics: 1-Naphthylamine; Adult; Age of Onset; Aged; Antidepressive Agents; Double-Blind Method; Dysthymic Di | 1997 |
The undertreatment of dysthymia.
Topics: 1-Naphthylamine; Adult; Age of Onset; Aged; Ambulatory Care; Antidepressive Agents; Comorbidity; Dys | 1997 |
A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia.
Topics: 1-Naphthylamine; Adult; Aged; Anger; Antidepressive Agents, Second-Generation; Antidepressive Agents | 1997 |
Treatment of dysthymia.
Topics: 1-Naphthylamine; Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents; Antidepressive Ag | 1997 |
Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Consti | 1997 |
The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies.
Topics: Antidepressive Agents, Tricyclic; Chronic Disease; Clinical Protocols; Comorbidity; Cross-Over Studi | 1998 |
The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Tricyclic; Chronic Disease; Comorbidity; Depres | 1998 |
The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine.
Topics: Adaptation, Psychological; Adult; Antidepressive Agents, Tricyclic; Chronic Disease; Comorbidity; De | 1998 |
Do tricyclic responders have different brain laterality?
Topics: Antidepressive Agents, Tricyclic; Brain; Depressive Disorder, Major; Dichotic Listening Tests; Doubl | 1999 |
Do tricyclic responders have different brain laterality?
Topics: Antidepressive Agents, Tricyclic; Brain; Depressive Disorder, Major; Dichotic Listening Tests; Doubl | 1999 |
Do tricyclic responders have different brain laterality?
Topics: Antidepressive Agents, Tricyclic; Brain; Depressive Disorder, Major; Dichotic Listening Tests; Doubl | 1999 |
Do tricyclic responders have different brain laterality?
Topics: Antidepressive Agents, Tricyclic; Brain; Depressive Disorder, Major; Dichotic Listening Tests; Doubl | 1999 |
Double-blind comparison of sertraline, imipramine, and placebo in the treatment of dysthymia: effects on personality.
Topics: Adult; Age of Onset; Antidepressive Agents, Tricyclic; Double-Blind Method; Dysthymic Disorder; Fact | 2000 |
Gender differences in treatment response to sertraline versus imipramine in chronic depression.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Tricyclic; Chronic Disease; Depressive Disorder | 2000 |
Are there differences by gender in response to pharmacotherapy for depression?
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Tricyclic; Chi-Squa | 2000 |
Sertraline versus imipramine to prevent relapse in chronic depression.
Topics: Adult; Aged; Chronic Disease; Cross-Over Studies; Depressive Disorder, Major; Double-Blind Method; D | 2001 |
Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression.
Topics: Adult; Cross-Over Studies; Depressive Disorder, Major; Dysthymic Disorder; Female; Humans; Imipramin | 2002 |
3 other studies available for imipramine and Dysthymia
| Article | Year |
|---|---|
Sertraline and imipramine for the treatment of dysthymia.
Topics: 1-Naphthylamine; Antidepressive Agents, Tricyclic; Dysthymic Disorder; Humans; Imipramine; Placebos; | 1997 |
Effects of antidepressant treatments on polymorphonuclear elastase levels in patients with depression.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Biomarkers; Depressive Disorder, Maj | 2000 |
Personality change after treatment.
Topics: Double-Blind Method; Dysthymic Disorder; Humans; Imipramine; Personality Assessment; Personality Dis | 2002 |